Wells Fargo
QNCX icon

Wells Fargo’s Quince Therapeutics QNCX Stock Holding History

Wells Fargo’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182 Buy
+10
New +$230 ﹤0.01% 6600
2026
Q1 		– Sell
-35
Closed -$23.4K – 7403
2025
Q4 		$23.4K Hold
35
– – ﹤0.01% 5755
2025
Q3 		$11.4K Hold
35
– – ﹤0.01% 5919
2025
Q2 		$11.5K Buy
+35
New +$8K ﹤0.01% 5916
2024
Q2 		– Sell
-1
Closed -$284 – 7351
2024
Q1 		$284 Sell
1
-5
-83% -$1.24K ﹤0.01% 6415
2023
Q4 		$1.33K Hold
6
– – ﹤0.01% 6164
2023
Q3 		$1.36K Buy
6
+5
+500% +$1.31K ﹤0.01% 6154
2023
Q2 		$232 Hold
1
– – ﹤0.01% 6658
2023
Q1 		$229 Hold
1
– – ﹤0.01% 6739
2022
Q4 		$92 Sell
1
-5
-83% -$836 ﹤0.01% 6814
2022
Q3 		$2K Sell
6
-1
-14% -$381 ﹤0.01% 6185
2022
Q2 		$3K Sell
7
-86
-92% -$60.8K ﹤0.01% 6211
2022
Q1 		$114K Sell
93
-89
-49% -$121K ﹤0.01% 5259
2021
Q4 		$459K Buy
182
+133
+271% +$812K ﹤0.01% 4728
2021
Q3 		$907K Sell
49
-13
-21% -$207K ﹤0.01% 4308
2021
Q2 		$657K Buy
62
+3
+5% +$25.2K ﹤0.01% 4478
2021
Q1 		$425K Sell
59
-99
-63% -$712K ﹤0.01% 4774
2020
Q4 		$878K Buy
158
+80
+103% +$709K ﹤0.01% 4124
2020
Q3 		$776K Sell
78
-15
-16% -$136K ﹤0.01% 4047
2020
Q2 		$859K Buy
93
+14
+18% +$128K ﹤0.01% 3927
2020
Q1 		$724K Buy
79
+11
+16% +$109K ﹤0.01% 3758
2019
Q4 		$766K Buy
68
+27
+66% +$163K ﹤0.01% 4042
2019
Q3 		$203K Buy
41
+19
+86% +$117K ﹤0.01% 4955
2019
Q2 		$191K Buy
+22
New +$131K ﹤0.01% 5003

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's QNCX Position: Q2 2026 in Review

Wells Fargo opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 10 shares worth $182. The stake represents ﹤0.01% of the portfolio and ranks #6600 among its holdings. This is a return to the name: Wells Fargo previously reported a position in QNCX as recently as Q4 2025.

Wells Fargo first reported a position in QNCX in Q2 2019 and has held it in 24 quarters since. The position peaked at $907K in Q3 2021. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Wells Fargo held 10 shares of Quince Therapeutics worth $182 as of Q2 2026.
  • Quince Therapeutics was a new Wells Fargo position in Q2 2026.
  • Quince Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6600 holding.
  • Wells Fargo first reported a position in Quince Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • Wells Fargo's Quince Therapeutics position peaked at $907K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.